Key Points

A groundbreaking blood test developed by researchers at Washington University and Lund University offers unprecedented insights into Alzheimer's disease progression. The test measures MTBR-tau243 protein levels with 92% accuracy, helping doctors distinguish between early and late-stage disease. This innovative diagnostic tool can potentially guide treatment decisions and provide clearer understanding of cognitive decline. The research, published in Nature Medicine, represents a significant advancement in neurodegenerative disease detection and management.

Key Points: Breakthrough Blood Test Reveals Alzheimer's Disease Progression

  • Innovative blood test measures MTBR-tau243 protein levels
  • Accurately distinguishes Alzheimer's disease stages
  • Provides insights for targeted treatment
  • Non-invasive diagnostic breakthrough
2 min read

New highly accurate blood test to measure progress of Alzheimer's

US researchers develop groundbreaking blood test to accurately diagnose and measure Alzheimer's disease stages with 92% precision

"This blood test clearly identifies Alzheimer's tau tangles - Randall J. Bateman, Washington University Neurologist"

New Delhi, March 31

US researchers have developed a new blood test that not only aids in the diagnosis of Alzheimer’s disease but also indicates how far it has progressed.

While currently available blood tests for Alzheimer’s disease can diagnose the disease, they do not indicate the clinical stage of the disease symptoms – that is, the degree of impairment in thinking or memory due to Alzheimer’s dementia.

The new test can help doctors determine which patients are likely to benefit from drug treatment and to what extent. It can also provide insight on whether a person’s symptoms are likely due to Alzheimer’s versus some other cause, said the researchers at Washington University School of Medicine in St. Louis, US and Lund University in Sweden.

In the study, published in the journal Nature Medicine, the researchers found that levels of a protein called MTBR-tau243 in the blood accurately reflect the amount of toxic accumulation of tau aggregates in the brain and correlate with the severity of Alzheimer’s disease.

Analysing blood levels of MTBR-tau243 from a group of people with cognitive decline, the researchers were able to distinguish between people with early- or later-stage Alzheimer’s disease and separate both groups of patients from people whose symptoms were caused by something other than Alzheimer’s.

“This blood test clearly identifies Alzheimer’s tau tangles, which is our best biomarker measure of Alzheimer’s symptoms and dementia,” said co-senior author Randall J. Bateman, Professor of Neurology at Washington University.

“In clinical practice right now, we don’t have easy or accessible measures of Alzheimer’s tangles and dementia, and so a tangle blood test like this can provide a much better indication if the symptoms are due to Alzheimer’s and may also help doctors decide which treatments are best for their patients,” he added.

The researchers developed a technique to measure MTBR-tau243 levels in people’s blood and compared it to the amount of tau tangles in their brains as measured by brain scans.

They piloted the approach on data from two cohorts: 108 people from the US, and a subset of 55 people from Sweden. To assess whether the approach was generalisable, they validated it in an independent dataset consisting of the remaining 739 people in Sweden.

The researchers’ analysis showed that blood MTBR-tau243 levels reflected the amount of tau tangles in the brain with 92 per cent accuracy.

- IANS

Share this article:

Reader Comments

S
Sarah K.
This is incredible news! My grandmother suffered from Alzheimer's and we never knew how advanced it was until it was too late. Having a simple blood test could help so many families prepare better. 🙏
M
Michael T.
The 92% accuracy rate is impressive, but I wonder how this compares to existing diagnostic methods. Also, what's the timeline for this becoming widely available? The article doesn't mention that.
A
Anika P.
As someone in the medical field, I'm excited but cautious. The sample sizes mentioned seem relatively small - 108 and 55 participants. Hope they expand testing to confirm these promising results!
J
James L.
Finally some good news in Alzheimer's research! The tau protein focus makes sense - it's been implicated in disease progression for years. Hope this leads to better personalized treatment options soon.
R
Rebecca S.
While this sounds promising, I worry about accessibility. Will this test be affordable for average patients? Alzheimer's already puts such financial strain on families. The article should address cost implications.
D
David M.
The part about distinguishing Alzheimer's from other causes of cognitive decline is huge! My dad was misdiagnosed twice before they got it right. This could prevent so much unnecessary suffering.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50